ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma.
dc.contributor.author | Abou-Alfa, G | |
dc.contributor.author | Qin, S | |
dc.contributor.author | Ryoo, B | |
dc.contributor.author | Lu, S | |
dc.contributor.author | Yen, C | |
dc.contributor.author | Feng, Y | |
dc.contributor.author | Lim, H | |
dc.contributor.author | Izzo, F | |
dc.contributor.author | Colombo, M | |
dc.contributor.author | Sarker, D | |
dc.contributor.author | Bolondi, L | |
dc.contributor.author | Vaccaro, G | |
dc.contributor.author | Harris, W | |
dc.contributor.author | Chen, Z | |
dc.contributor.author | Hubner, Richard A | |
dc.contributor.author | Meyer, T | |
dc.contributor.author | Sun, W | |
dc.contributor.author | Harding, J | |
dc.contributor.author | Hollywood, E | |
dc.contributor.author | Ma, J | |
dc.contributor.author | Wan, P | |
dc.contributor.author | Ly, M | |
dc.contributor.author | Bomalaski, J | |
dc.contributor.author | Johnston, A | |
dc.contributor.author | Lin, C | |
dc.contributor.author | Chao, Y | |
dc.contributor.author | Chen, L | |
dc.date.accessioned | 2018-05-10T20:22:45Z | |
dc.date.available | 2018-05-10T20:22:45Z | |
dc.date.issued | 2018-04-05 | |
dc.identifier.citation | ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma. 2018, Ann Oncol | en |
dc.identifier.issn | 1569-8041 | |
dc.identifier.pmid | 29659672 | |
dc.identifier.doi | 10.1093/annonc/mdy101 | |
dc.identifier.uri | http://hdl.handle.net/10541/620997 | |
dc.description.abstract | Arginine depletion is a putative target in hepatocellular carcinoma (HCC). HCC often lacks argininosuccinate synthetase, a citrulline to arginine-repleting enzyme. ADI-PEG 20 is a cloned arginine degrading enzyme - arginine deiminase - conjugated with polyethylene glycol. The goal of this study was to evaluate this agent as a potential novel therapeutic for HCC after first line systemic therapy. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to Annals of oncology : official journal of the European Society for Medical Oncology | en |
dc.title | ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma. | en |
dc.type | Article | en |
dc.contributor.department | Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY | en |
dc.identifier.journal | Annals of Oncology | en |
html.description.abstract | Arginine depletion is a putative target in hepatocellular carcinoma (HCC). HCC often lacks argininosuccinate synthetase, a citrulline to arginine-repleting enzyme. ADI-PEG 20 is a cloned arginine degrading enzyme - arginine deiminase - conjugated with polyethylene glycol. The goal of this study was to evaluate this agent as a potential novel therapeutic for HCC after first line systemic therapy. |